All News

24 August 2009

Lpath Achieves Merck Serono MilestoneAntibodies

18 August 2009

Lpath Completes Enrollment of Patients in iSONEP(TM) Phase 1 Clinical TrialAntibodies

18 August 2009

Neurimmune Therapeutics Announces Advancement of Alzheimer’s Program into Preclinical DevelopmentAntibodies

18 August 2009

GLAXOSMITHKLINE AND GENMAB ANNOUNCE RESULTS FROM A STUDY OF ARZERRA IN RITUXIMAB REFRACTORY FOLLICULAR NHLAntibodies

18 August 2009

Crucell Receives NIH Award for the Development of Influenza Monoclonal AntibodiesAntibodies

17 August 2009

Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast CancerAntibodies

17 August 2009

Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal CancerAntibodies

14 August 2009

Immunomedics Announces FDA Allowance of Investigational New Drug Application for Milatuzumab-Doxorubicin ConjugateAntibodies

14 August 2009

Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) MeetingAntibodies

11 August 2009

GENMAB ANNOUNCES PRELIMINARY TOP-LINE RESULTS FOR ARZERRA™ IN FRONT LINE CLLAntibodies

11 August 2009

BioInvent Announces Approval to start Phase I Trial for BI-505 in Multiple MyelomaAntibodies

10 August 2009

MedImmune Advances Three Oncology Programs Into the ClinicAntibodies

9 August 2009

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal CancerAntibodies

7 August 2009

Antisoma announces discontinuation of development of AS1402Antibodies

5 August 2009

PharmaGap Releases Results of Initial Testing For Novel Cancer Drug Compound at the Ottawa Hospital Research InstituteAntibodies

5 August 2009

FDA: Cancer Warnings Required for TNF BlockersAntibodies

4 August 2009

Facet Biotech Announces Daclizumab Program in Multiple Sclerosis to AdvanceAntibodies

4 August 2009

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)Antibodies

3 August 2009

FDA Approves Avastin for the Most Common Type of Kidney CancerAntibodies

3 August 2009

Merck KGaA Presented New Data On the Combination of Erbitux with Standard First-Line Therapy in Patients with NSCLCAntibodies

31 July 2009

ImmunoGen Announces Encouraging New Clinical Data with the Company’s IMGN901 Compound in the Treatment of Small-Cell Lung CancerAntibodies

31 July 2009

Merck KGaA Has Requested Re-examination of the CHMP Opinion for Erbitux in Non-Small Cell Lung CancerAntibodies

31 July 2009

BioInvent signs Licensing Agreement with Mitsubishi Tanabe Pharma Corporation for the Discovery and Development of Therapeutic AntibodiesAntibodies

31 July 2009

Update on FDA Registration of Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody for Rheumatoid ArthritisAntibodies

30 July 2009

ArmaGen engineers IgG-decoy receptor fusion proteinAntibodies

30 July 2009

Second Phase III Study Showed Lucentis Improved Vision in Patients with Retinal Vein OcclusionAntibodies

30 July 2009

Merck Serono and MSM Protein Technologies Establish Drug Discovery Collaboration Targeted to Complex Cell Surface ReceptorsAntibodies

30 July 2009

Debiopharm and MSM Protein Technologies sign agreement for Research and Development of Debio 0929, a Novel Oncology BiologicAntibodies

30 July 2009

GLAXOSMITHKLINE AND GENMAB ANNOUNCE TOP-LINE RESULTS FOR OFATUMUMAB IN RHEUMATOID ARTHRITISAntibodies

29 July 2009

Regulatory update: mepolizumab for the treatment of hypereosinophilic syndrome (HES)Antibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Ustekinumab (Stelara) Biosimilars Pipeline Review

TL1A Inhibitor Pipeline Review

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

Adalimumab (Humira) Biosimilars Pipeline Review

CD73 Inhibitor Pipeline Review

DLL3-Targeted Immunotherapy Candidates Pipeline Review

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review